Exane Derivatives’s Synergy Pharmaceuticals, Inc Common Stock SGYP Stock Holding History

Exane Derivatives’s Portfolio SGYP Stock Details SGYP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1	Closed	-$2	–	760
2018 Q3	$2	Hold	1	–	–	﹤0.01%	693
2018 Q2	$2	Hold	1	–	–	﹤0.01%	686
2018 Q1	$2	Sell	1 -107,978	-100%	-$228K	﹤0.01%	626
2017 Q4	$241K	Buy	107,979 +47,774	+79%	+$119K	0.04%	225
2017 Q3	$175K	Buy	60,205 +52,722	+705%	+$180K	0.03%	204
2017 Q2	$33.3K	Buy	+7,483	New	+$30.9K	0.01%	342

Other funds holding SGYP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

OCM

Opti Capital Management New York $1.64B AUM 0% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Exane Derivatives's SGYP Position: Q4 2018 in Review

Exane Derivatives sold out of Synergy Pharmaceuticals, Inc Common Stock (SGYP) in Q4 2018, closing a stake of 1 share — an estimated $2 sold.

Exane Derivatives first reported a position in SGYP in Q2 2017 and held it in 6 quarters. The position peaked at $241K in Q4 2017. 89 funds tracked by Wall St. Rank hold SGYP as of Q4 2018.

Exane Derivatives reported no remaining Synergy Pharmaceuticals, Inc Common Stock position as of Q4 2018 after selling out during the quarter.
Exane Derivatives sold 1 Synergy Pharmaceuticals, Inc Common Stock share in Q4 2018, an estimated $2.
Exane Derivatives first reported a position in Synergy Pharmaceuticals, Inc Common Stock in Q2 2017 and held it in 6 quarters.
Exane Derivatives's Synergy Pharmaceuticals, Inc Common Stock position peaked at $241K in Q4 2017.
89 funds tracked by Wall St. Rank held Synergy Pharmaceuticals, Inc Common Stock as of Q4 2018.

Based on Exane Derivatives's 13F filing for Q4 2018, filed 31 Jan 2019.